Evidence map›Paper›PMID 39070823›Full record

ArticleWorld journal of clinical cases2024

Hepatoid adenocarcinoma of the lung: A case report.

Yi-Jun Mo, Li-Na Lin, Jing-Li Tao, Tao Zhang, Jian-Hua Zhang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yi-Jun MoDepartment of Thoracic Surgery, Shenzhen Hospital, Southern Medical University, Shenzhen 518104, Guangdong Province, China.
Li-Na LinSchool of Nursing, Guangzhou Xinhua University, Guangzhou 510520, Guangdong Province, China. linlinadr@163.com.
Jing-Li TaoDepartment of Pathology, Shenzhen Hospital, Southern Medical University, Shenzhen 518104, Guangdong Province, China.
Tao ZhangDepartment of Thoracic Surgery, Shenzhen Hospital, Southern Medical University, Shenzhen 518104, Guangdong Province, China.
Jian-Hua ZhangDepartment of Thoracic Surgery, Shenzhen Hospital, Southern Medical University, Shenzhen 518104, Guangdong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatoid adenocarcinoma of the lung (HAL) is a rare type of non-small cell lung cancer (NSCLC), histologically similar to hepatocellular carcinoma. HAL has high malignancy and poor prognosis, and a better treatment plan needs further study. CASE SUMMARY: In order to deeply understand the occurrence and development of HAL, here we report a case of HAL with extensive metastasis of alpha fetoprotein negative KRAS A146T mutation. The patient refused chemotherapy and received one course of treatment (immune checkpoint inhibitors), and died three months later due to progressive disease.

conclusionHAL is a special type of NSCLC. The surgical treatment of HAL in the limited stage can achieve long-term survival, but most of them were in the advanced stage when they were found, and the prognosis was poor, which requires multidisciplinary comprehensive treatment.

Indexed as

Case reportHepatoid adenocarcinomaHepatoid adenocarcinoma of the lungHistopathological characteristicsNon-small cell lung cancer

Identifiers

PMID39070823
PMCPMC11235510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.